Reuters logo
BRIEF-Idera Pharmaceuticals presents positive translational and clinical data update from ongoing IMO-2125 development program
November 9, 2017 / 1:01 PM / a month ago

BRIEF-Idera Pharmaceuticals presents positive translational and clinical data update from ongoing IMO-2125 development program

Nov 9 (Reuters) - Idera Pharmaceuticals Inc

* Idera Pharmaceuticals Inc presents positive translational and clinical data update from ongoing IMO-2125 development program at the 2017 society for immunotherapy of cancer annual meeting (SITC)

* Idera Pharmaceuticals Inc - additional 5th unconfirmed recist v1.1 response observed in 10th evaluable patient from ongoing imo-2125 8mg phase 2 dose expansion cohort​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below